EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
MAR 2024
-
EDITION 9
-
TABLES 97
-
REGIONS 12
-
SEGMENTS 6
-
PAGES 220
-
US$ 4950
-
MCP11652
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
© Copy rights Global Industry Analysts, Inc., USA. www.strategyr.com All Rights Reserved.
OUR EXPERT PANELS
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
WHY PARTICIPATE?
Expertise to the Power of YOU!
- Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
- Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
- Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
- Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
- Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription
- The Economist
- MIT Technology Review
- Harvard Business Review
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
MARKETGLASS
BASIC
- Annual Prepaid Subscription
- Single-User
- 10,000 Data Room Credits/Month
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use MarketGlassTM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
PREMIUM
- Annual Prepaid Subscription
- One Research Project With One Complimentary Update/Year
- 10-User License
- 10-User Peer-to-Peer Collaborative Features
- 200 Domain Expert Insights (With Name, Company, and Date)
- 50,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
ENTERPRISE
- Annual Prepaid Subscription
- Four Research Projects With One Complimentary Update/Year
- 25-User License
- 25-User Peer-to-Peer Collaborative Engagements
- 500 Domain Expert Insights (With Name, Company, and Date)
- 150,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
HIGHLIGHTS & REPORT INDEX
Global Duchenne Muscular Dystrophy Drugs Market to Reach $27.4 Billion by 2030
The global market for Duchenne Muscular Dystrophy Drugs estimated at US$2.8 Billion in the year 2023, is expected to reach US$27.4 Billion by 2030, growing at a CAGR of 33% over the period 2023-2030. Exon Skipping, one of the segments analyzed in the report, is expected to record 37.5% CAGR and reach US$18.1 Billion by the end of the analysis period. Growth in the Steroid Therapy segment is estimated at 23.4% CAGR for the next 8-year period.
The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 38.5% CAGR
The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 38.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 27.5% and 26.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 29.1% CAGR.
Introducing Our Exciting New Report Features for 2024
» Full access to influencer engagement stats
» Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants` privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
» Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
» Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
» Complimentary report updates for one year
» Competitor coverage with global market shares of major players
» Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
» Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
SELECT PLAYERS
FibroGen, Inc.; ITALFARMACO S.p.A.; NS Pharma Inc.; PTC Therapeutics, Inc.; Sarepta Therapeutics, Inc.; Satellos Bioscience, Inc.
SEGMENTS
» Segment (Exon Skipping, Steroid Therapy, Mutation Suppression, Other Segments)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
A Prelude to Duchenne Muscular Dystrophy |
Global Economic Update |
Here’s How Inflationary Pressures Affect the Economy |
Here’s What’s Causing Inflationary Pressures in the Global Market |
EXHIBIT: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024 |
Impact of COVID-19 on Duchenne Muscular Dystrophy Drugs Market |
Competition |
Product Development as Hallmark of Global Duchenne Muscular Dystrophy Market |
Duchenne Muscular Dystrophy Drugs – Global Key Competitors Percentage Market Share in 2023 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 38 Players Worldwide in 2023 (E) |
Global Market Overview and Prospects |
Global Duchenne Muscular Dystrophy Drugs Market Set for a Rapid Growth, Driven by Rising Prevalence |
A Review of the Approved DMD Drugs |
North America and Europe to Remain Lucrative Markets |
Molecular Therapy, Hospital/Clinic & Hospital Pharmacy: Hale & Hearty Segments of Duchenne Muscular Dystrophy Market |
Dynamic Factors Keeping Duchenne Muscular Dystrophy Market Growing |
Market Drivers |
Market Restraints & Challenges |
Market Opportunities |
Recent Market Activity |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Rising R&D Investment to Boost DMD Market |
EXHIBIT: Select Therapy Candidates Under Development for Treating DMD |
Growing Government Support Propels Market Expansion |
Biologics - The Most Dynamic Segment of the Market |
Blossoming of Gene Therapy in Duchenne Muscular Dystrophy Treatment Domain |
Gene Therapy for DMD Treatment |
Elevidys, The First Ground-breaking Gene Therapy for Treatment of Duchenne Muscular Dystrophy (DMD) |
Children’s National Hospital Starts Offering Newly Approved Gene Therapy for DMD |
Promising Gene Therapies |
Potential Side-Effects & Risks of Gene Therapies |
Vamorolon Holds Potential to Lessen Health Risks Linked with Extended Use of Steriods |
DT-DEC01 Offers Promise to Stabilize or Improve Motor Function |
AOC 1044 Receives Orphan Drug Status for DMD44 |
Italfarmaco Group Announces NDA Acceptance for Givinostat Targeting Duchenne Muscular Dystrophy |
Uptrend in Healthcare Expenditure Creates Substantial Opportunities |
EXHIBIT: World Healthcare Expenditure (In US$ Trillion) for the Years 2019, 2021 & 2023 |
4. GLOBAL MARKET PERSPECTIVE |
World Duchenne Muscular Dystrophy Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2018 through 2030 |
World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Exon Skipping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Steroid Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Other Therapeutic Approaches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Drug Store & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
World 12-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
USA Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
JAPAN |
Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
CHINA |
China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
China Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
China Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
EUROPE |
Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR |
Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
FRANCE |
France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
France Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
France Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
GERMANY |
Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
UNITED KINGDOM |
UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
UK Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
ASIA-PACIFIC |
Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2024 & 2030 |
Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR |
Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2022 and % CAGR |
Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2024 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
DIFFERENTIATORS
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
WHAT SETS US APART
FULL STACK DATA ACCESS
- Primary Research Cluster Data
- Influencer Engagement Stats
- Evidence of Primary Research
- List of Companies Engaged
- Hundreds of Pages of Research
- Peer Collaborative Interactions
- Enterprise Data Exchanges
- MarketGlassTM Platform Insider
- Geographic Pricing Dynamics
- Competitive Shares by Country
- Brand Curation & Insights
- Domain Expert Pool
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.